文献速递支持与姑息治疗胸部肿瘤消化系统肿瘤

实体器官移植受者移植前癌症史与移植后癌症风险

Cancer Risk in Solid Organ Transplant Recipients With a Pretransplant Cancer History.
PubMed 文献 · JAMA Oncol · 2026-01-01

结果显示7种移植前癌症与同类型移植后癌症风险显著升高相关,部分跨癌种组合亦显著;靶向预防和筛查可能使移植前有癌症史的受者获益。

要点

  • 移植前乳腺癌、黑色素瘤、肺癌、肾癌、膀胱癌、肝癌、结直肠癌与同类型移植后癌症风险升高显著相关。
  • 肝癌后肺癌、肝癌后前列腺癌、膀胱癌后肺癌、肾癌后甲状腺癌、肝内胆管癌后胰腺癌风险亦显著升高。
  • 肝-肝、肾-肾、肺-肺三种组合的IRR低于一般人群癌症幸存者的相应SIR。

核心结论

  • 实体器官移植受者若有移植前癌症史,移植后癌症风险升高,尤其同类型癌症。
  • 这些模式可能反映共享的遗传或环境危险因素。
  • 移植前有肾、肝或肺癌的受者,移植后同器官癌症可能与终末期器官疾病相关。
  • 针对性的癌症预防和筛查可能使移植前有癌症史的移植受者获益。

研究设计与样本

  • 队列研究,链接美国移植受者科学登记与34个基于人群的癌症登记数据,覆盖1995–2019年美国92%的实体器官移植受者。
  • 暴露为移植前癌症诊断,主要结局为移植后癌症风险,按达到年龄、性别和移植器官校正。
  • 比较581种移植前与移植后癌症类型组合的发病率比(IRR),并与标准化发病率比(SIR)比较。
  • 数据分析时间为2025年3月至9月。

主要发现

  • 移植前乳腺癌与移植后乳腺癌风险升高相关(IRR 3.71,95%CI 3.04–4.48)。
  • 移植前皮肤黑色素瘤与移植后皮肤黑色素瘤风险升高相关(IRR 10.4,95%CI 7.43–14.1)。
  • 移植前肺癌与移植后肺癌风险升高相关(IRR 3.65,95%CI 2.67–4.86)。
  • 移植前肾癌与移植后肾癌风险升高相关(IRR 2.34,95%CI 1.94–2.79);移植前膀胱癌与移植后膀胱癌风险升高相关(IRR 3.72,95%CI 2.44–5.39)。
  • 移植前肝癌与移植后肝癌风险升高相关(IRR 1.73,95%CI 1.39–2.14);移植前结直肠癌与移植后结直肠癌风险升高相关(IRR 2.38,95%CI 1.61–3.37)。

关键数值与推荐

  • 7种移植前癌症与同类型移植后癌症风险显著相关,Bonferroni校正P值<8.6×10⁻⁵。
  • 移植前肝癌后肺癌IRR 1.63(95%CI 1.48–1.80),肝癌后前列腺癌IRR 1.71(95%CI 1.53–1.92)。
  • 移植前膀胱癌后肺癌IRR 2.55(95%CI 1.93–3.29),肾癌后甲状腺癌IRR 2.87(95%CI 1.87–4.17)。
  • 移植前肝内胆管癌后胰腺癌IRR 8.56(95%CI 3.66–16.7)。
  • 肝-肝、肾-肾、肺-肺三种组合的IRR低于一般人群癌症幸存者的相应SIR。

临床怎么用

  • 对移植前有癌症史的实体器官移植受者,应关注移植后同类型及特定跨类型癌症风险。
  • 可考虑针对移植前癌症史制定个体化移植后癌症预防和筛查策略。
  • 移植前有肾、肝或肺癌者,移植后需关注同器官癌症与终末期器官疾病的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Cancer survivors are at elevated risk of developing subsequent cancers. Solid organ transplant (SOT) recipients also have elevated cancer risk, but the pattern of subsequent cancer risk among SOT recipients with a pretransplant cancer has not been studied. OBJECTIVE: To assess the association of pretransplant cancers with posttransplant cancer risk among SOT recipients. DESIGN, SETTING, AND PARTICIPANTS: This cohort study used linked data from the US Scientific Registry of Transplant Recipients and 34 population-based cancer registries, comprising 92% of the US SOT recipient population from 1995 to 2019. Data were analyzed from March to September 2025. EXPOSURE: Pretransplant cancer diagnosis. MAIN OUTCOME AND MEASURES: Incidence rate ratios (IRRs) were used to compare risk of posttransplant cancer among SOT recipients with vs without pretransplant cancer, adjusted for attained age, sex, and transplanted organ, for 581 combinations of pretransplant and posttransplant cancer types. IRRs were compared with standardized incidence ratios (SIRs), which assess subsequent cancer risk among cancer survivors in the general population, using US cancer registry data. RESULTS: A total of 520 424 SOT recipients were evaluated in the analysis; the median (IQR) age at transplant was 52 (41-59) years. Seven types of pretransplant cancer were significantly associated with a risk of the same type of cancer after transplant (Bonferroni-corrected P value <8.6 × 10-5): breast (IRR, 3.71, 95% CI, 3.04-4.48), melanoma of the skin (IRR, 10.4; 95% CI, 7.43-14.1), lung (IRR, 3.65; 95% CI, 2.67-4.86), kidney (IRR, 2.34; 95% CI, 1.94-2.79), urinary bladder (IRR, 3.72; 95% CI, 2.44-5.39), liver (IRR, 1.73; 95% CI, 1.39-2.14), and colorectum (IRR, 2.38; 95% CI, 1.61-3.37). Other significant associations included liver followed by lung cancer (IRR, 1.63; 95% CI, 1.48-1.80) or by prostate cancer (IRR, 1.71; 95% CI, 1.53-1.92), urinary bladder followed by lung cancer (IRR, 2.55; 95% CI, 1.93-3.29), kidney followed by thyroid cancer (IRR, 2.87; 95% CI, 1.87-4.17), and intrahepatic bile duct followed by pancreatic cancer (IRR, 8.56; 95% CI, 3.66-16.7). These IRRs were lower than the corresponding SIRs for cancer survivors in the general population for 3 combinations of pretransplant and posttransplant cancer types (liver-liver, kidney-kidney, and lung-lung). CONCLUSIONS AND RELEVANCE: This cohort study found that SOT recipients with pretransplant cancer had an elevated risk of posttransplant cancer, particularly of the same cancer type. These patterns likely reflect shared genetic or environmental risk factors. Among SOT recipients who had kidney, liver, or lung cancer before transplant, posttransplant cancer of the same organ may be associated with the underlying end-stage organ disease. Targeted cancer prevention and screening could benefit SOT recipients who have survived a cancer diagnosis before a transplant.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Tao J, Pfeiffer RM, Ahmed S, et al. Cancer Risk in Solid Organ Transplant Recipients With a Pretransplant Cancer History. JAMA Oncol. 2026. PMID: 41817522. doi:10.1001/jamaoncol.2026.0206

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。